FDA breakthrough therapy designation targets HPV-unrelated recurrent/metastatic HNSCC after progression on platinum-based chemotherapy and PD-1/PD-L1 inhibitors, aiming to accelerate development and ...

The FDA rejected AstraZeneca's subcutaneous Saphnelo application, delaying U.S. approval until 2026, despite positive clinical trial results. The subcutaneous formulation allows self-administration, ...

Subcutaneous (SC) formulations of monoclonal antibodies are rapidly transforming the delivery of cancer immunotherapy. Designed to replace or complement intravenous (IV) administration, SC delivery ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved a subcutaneous induction regimen of guselkumab for the treatment of adults with moderately ...

Merck (NYSE:MRK) said that the FDA has cleared Keytruda Qlex, a new subcutaneous version of its blockbuster cancer drug, offering a faster alternative to IV infusion, a company spokesperson confirmed ...

Sept 19 (Reuters) - E-commerce accelerator Pattern Group (PTRN.O), opens new tab on Friday notched a valuation of $2.38 billion as its shares fell 3.6% in their Nasdaq debut, bucking the recent trend ...

The FDA has approved Merck & Co.’s under-the-skin version of Keytruda, reducing treatment time burden for patients while granting the world’s bestselling drug potential blockbuster revenue protection.

Pattern made its debut on the Nasdaq after raising $300 million for the company and its investors in an IPO. The Utah-based company is one of the top sellers on Amazon's third-party marketplace. "No ...

FDA approved pembrolizumab and berahyaluronidase alfa-pmph for patients aged 12 and older with solid tumors. Study MK-3475A-D77 showed a 45% ORR in subcutaneous administration for treatment-naïve ...

Sept 18 (Reuters) - Pattern and its existing shareholders raised $300 million in its U.S. initial public offering on Thursday, after the e-commerce firm priced its shares within the marketed range.

Please provide your email address to receive an email when new articles are posted on . Patients who received subcutaneous amivantamab-vmjw every 4 weeks plus lazertinib had similar outcomes as those ...

A six-month-old male Brazilian Terrier with persistent cough and dyspnea was diagnosed with intrathoracic tracheal collapse and pneumonia after chest radiographics. The medical treatment was performed ...